Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMT NASDAQ:AKCA NASDAQ:LGND NYSE:PBH NASDAQ:PCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMTAimmune Therapeutics$34.49$34.46$10.09▼$37.00$2.26B1.761.71 million shsN/AAKCAAkcea Therapeutics$18.17$18.16$8.00▼$21.70$1.85B1.45361,806 shsN/ALGNDLigand Pharmaceuticals$128.62+3.5%$110.23$90.29▼$130.68$2.47B0.84117,091 shs165,536 shsPBHPrestige Consumer Healthcare$74.75-0.5%$83.52$64.94▼$90.04$3.69B0.43312,822 shs119,577 shsPCRXPacira BioSciences$22.77+0.2%$24.71$11.16▼$27.64$1.05B0.48893,859 shs141,289 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMTAimmune Therapeutics0.00%0.00%0.00%0.00%0.00%AKCAAkcea Therapeutics0.00%0.00%0.00%0.00%0.00%LGNDLigand Pharmaceuticals-2.06%+7.97%+10.49%+18.81%+28.58%PBHPrestige Consumer Healthcare-1.82%-4.63%-10.43%-5.98%+6.16%PCRXPacira BioSciences-2.49%-1.94%-6.23%-7.11%+6.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMTAimmune TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAKCAAkcea TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ALGNDLigand Pharmaceuticals4.0438 of 5 stars2.51.00.04.42.13.31.9PBHPrestige Consumer Healthcare4.4002 of 5 stars3.32.00.03.53.81.71.9PCRXPacira BioSciences3.0713 of 5 stars2.21.00.03.92.12.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMTAimmune Therapeutics 0.00N/AN/AN/AAKCAAkcea Therapeutics 0.00N/AN/AN/ALGNDLigand Pharmaceuticals 3.00Buy$147.1714.42% UpsidePBHPrestige Consumer Healthcare 2.50Moderate Buy$93.3324.86% UpsidePCRXPacira BioSciences 2.33Hold$26.4416.14% UpsideCurrent Analyst Ratings BreakdownLatest LGND, AIMT, AKCA, PCRX, and PBH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$142.00 ➝ $145.005/9/2025PCRXPacira BioSciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$32.00 ➝ $30.005/8/2025PBHPrestige Consumer HealthcareRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMTAimmune TherapeuticsN/AN/AN/AN/A$1.66 per shareN/AAKCAAkcea Therapeutics$488.54M3.78$0.51 per share35.54$5.78 per share3.14LGNDLigand Pharmaceuticals$167.13M14.85$1.63 per share78.99$43.95 per share2.93PBHPrestige Consumer Healthcare$1.14B3.25$5.10 per share14.66$37.04 per share2.02PCRXPacira BioSciences$702.77M1.50$4.22 per share5.40$16.86 per share1.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMTAimmune Therapeutics-$248.50M-$3.97N/AN/AN/AN/A-164.99%-89.50%N/AAKCAAkcea Therapeutics$40.77M$0.48N/AN/AN/A-12.34%-8.94%-8.02%N/ALGNDLigand Pharmaceuticals-$4.03M-$7.12N/A34.67N/A-73.07%-7.83%-6.92%8/5/2025 (Estimated)PBHPrestige Consumer Healthcare$214.60M$4.2917.4215.702.2918.86%12.87%6.78%8/6/2025 (Estimated)PCRXPacira BioSciences-$99.56M-$2.28N/A8.86N/A-14.78%13.78%7.00%7/29/2025 (Estimated)Latest LGND, AIMT, AKCA, PCRX, and PBH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025LGNDLigand Pharmaceuticals$1.54N/AN/AN/A$43.87 millionN/A7/29/2025Q2 2025PCRXPacira BioSciences$0.73N/AN/AN/A$183.11 millionN/A5/8/2025Q1 2025LGNDLigand Pharmaceuticals$1.23$1.33+$0.10-$2.21$37.84 million$45.33 million5/8/2025Q4 2025PBHPrestige Consumer Healthcare$1.30$1.32+$0.02$1.00$289.36 million$296.52 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMTAimmune TherapeuticsN/AN/AN/AN/AN/AAKCAAkcea TherapeuticsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/APBHPrestige Consumer HealthcareN/AN/AN/AN/AN/APCRXPacira BioSciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMTAimmune Therapeutics0.737.537.40AKCAAkcea TherapeuticsN/A12.1711.78LGNDLigand PharmaceuticalsN/A5.275.02PBHPrestige Consumer Healthcare0.554.202.82PCRXPacira BioSciences0.482.411.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMTAimmune Therapeutics74.47%AKCAAkcea Therapeutics19.27%LGNDLigand Pharmaceuticals91.28%PBHPrestige Consumer Healthcare99.95%PCRXPacira BioSciences99.73%Insider OwnershipCompanyInsider OwnershipAIMTAimmune Therapeutics13.75%AKCAAkcea Therapeutics1.50%LGNDLigand Pharmaceuticals7.00%PBHPrestige Consumer Healthcare1.40%PCRXPacira BioSciences6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMTAimmune Therapeutics22865.45 millionN/AOptionableAKCAAkcea Therapeutics248101.60 millionN/AOptionableLGNDLigand Pharmaceuticals8019.29 million17.94 millionOptionablePBHPrestige Consumer Healthcare54049.42 million48.72 millionOptionablePCRXPacira BioSciences72046.29 million43.33 millionOptionableLGND, AIMT, AKCA, PCRX, and PBH HeadlinesRecent News About These CompaniesInvestors who lost money with shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) should contact the Shareholders Foundation in connection with Lawsuit5 hours ago | prnewswire.comPacira BioSciences, Inc. (NASDAQ:PCRX) Given Consensus Rating of "Hold" by BrokeragesJuly 13 at 4:24 AM | marketbeat.comAllspring Global Investments Holdings LLC Makes New $277,000 Investment in Pacira BioSciences, Inc. (NASDAQ:PCRX)July 12, 2025 | marketbeat.comNon-opioid pain drug maker Pacira lays off 71 in California, retires facility in manufacturing upgradeJuly 11, 2025 | fiercepharma.comFPacira BioSciences to Close Manufacturing Suite, Lay Off 71 EmployeesJuly 10, 2025 | marketwatch.comPacira announces layoffs due to efficiencies in Exparel productionJuly 10, 2025 | msn.comPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 3, 2025 | globenewswire.comRobeco Institutional Asset Management B.V. Purchases 12,750 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)July 2, 2025 | marketbeat.comPacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025June 18, 2025 | finance.yahoo.comIs the Options Market Predicting a Spike in Pacira BioSciences Stock?June 18, 2025 | zacks.comPacira BioSciences, Inc. (NASDAQ:PCRX) Receives Average Rating of "Hold" from AnalystsJune 18, 2025 | marketbeat.comPACIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Pacira BioSciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmJune 17, 2025 | globenewswire.comPacira Pharmaceuticals Stockholders Approve Amended Incentive PlanJune 13, 2025 | tipranks.comPacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the InvestigationJune 8, 2025 | accessnewswire.comALauren Riker Sells 5,578 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) StockJune 7, 2025 | insidertrades.comPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 5, 2025 | globenewswire.comPacira BioSciences’s First Quarter 2025 Misses EstimatesMay 29, 2025 | ryortho.comRBronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Reach OutMay 25, 2025 | accessnewswire.comAPacira at RBC Conference: Strategic Growth and Gene Therapy FocusMay 23, 2025 | uk.investing.comPacira BioSciences (NASDAQ:PCRX) adds US$78m to market cap in the past 7 days, though investors from three years ago are still down 57%May 22, 2025 | finance.yahoo.comPacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare ConferencesMay 14, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLGND, AIMT, AKCA, PCRX, and PBH Company DescriptionsAimmune Therapeutics NASDAQ:AIMTAimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.Akcea Therapeutics NASDAQ:AKCAAkcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.Ligand Pharmaceuticals NASDAQ:LGND$128.62 +4.32 (+3.48%) As of 01:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.Prestige Consumer Healthcare NYSE:PBH$74.75 -0.40 (-0.53%) As of 01:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.Pacira BioSciences NASDAQ:PCRX$22.77 +0.04 (+0.18%) As of 01:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Delta Air Lines Stock Rallies on New Guidance—Can It Keep Going? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
